Evidence map›Paper›PMID 30050498›Full record

ReviewFrontiers in endocrinology2018

Tributyltin and Vascular Dysfunction: The Role of Oxidative Stress.

Karoline de Sousa Ronconi, Ivanita Stefanon, Rogerio F Ribeiro Junior

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Karoline de Sousa RonconiDepartment of Physiological Sciences, Federal University of Espírito Santo, Vitória, Brazil.
Ivanita StefanonDepartment of Physiological Sciences, Federal University of Espírito Santo, Vitória, Brazil.
Rogerio F Ribeiro JuniorDepartment of Physiological Sciences, Federal University of Espírito Santo, Vitória, Brazil.
Universidade Federal do Espírito Santo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The organotin compounds (OT) are used as fungicides, stabilizers in plastics, miticides, manufacturing and agricultural biocides, wood preservatives and antifouling agents. Tributyltin (TBT) is an OT that was first used for antifouling because it was the most effective agent to prevent undesirable accumulation of marine organisms on solid surfaces, such as ships' hulls or mechanical components, immersed in saltwater. TBT can be easily absorbed by mammals through ingestion, and its cytotoxic effects have become a major concern since their discovery in the 1970s. Recently, it has been demonstrated that TBT exposure is detrimental to the cardiovascular system. TBT is a membrane active substance and its action seems to depend on the OT lipophilicity. As a result, TBT crosses the cell membrane and damages the endothelium and the smooth muscle cells. TBT exposure induces vascular dysfunction, most likely due to endothelial dysfunction and morphological changes in the vascular wall. In an experimental rodent model, small doses of TBT (100 and 500 ng/kg/bw/day for 15 days) modified the vascular reactivity in aorta, mesenteric and coronary arteries followed by smooth muscle cell atrophy, increased collagen deposition and fibrin accumulation. TBT exposure increases oxidative stress by inducing vascular superoxide anion production derived from NADPH oxidase and decreases nitric oxide (NO) production as well as eNOS protein expression. The goal of this review is to summarize the current state of the art regarding the mechanisms involved in the vascular and endothelial dysfunction induced by TBT.

Indexed as

endothelial dysfunctionNADPH oxidasenitric oxideorganotin compoundstributyltinvascular dysfunction

Identifiers

PMID30050498
PMCPMC6052083
OpenAlexW2832034318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.